DEA

Fragster2020

Fact is Taco threw a stone at the hornets nest but didn't expect to be surrounded with hornets so now he's knee deep in his own shit but no escape and with mid terms coming up, he'll grasping straws to stay float. America is in deep shit.....housing market is about to collapse, inflation is rising so quick, congress is unable to counter it, all their DEA policies are coming back and biting them in the back. Mid class is struggling and when this happens, u know shit is about to hit the fan. So hold on to your cash and think outside stocks. Most of stocks were overvalued so the market is now settling. AI is doing the rest of the damage to the economy with massive layoffs (and incoming by end of year).

Ok_Recording_4440

Yeah I get that explanation but wtf is the DEA doing? They have more of a narrow focus….drugs. This drug happens to be medicinal in 40 states, needs to be researched and reformed obviously.

volckerwasright

Dates for the 2026 DEA supply chain conference are April 2, 7,8,9,16, 2026. https://deadiversion.usdoj.gov/mtgs/meetings.html

KAI5ER

I remember a hearing where Gatez asked the head of the DEA if they could work in tandem with the HHS on rescheduling. She bluntly said no. Nothing was started till AFTER the DOJ got the official EO from he white house. Everything they do is in 30 day windows.

Gambelero

Translate your quote in the first sentence. What exactly needs to be done with no legal holes? To me, that means they’re working on a new state of the science report, one that the DEA’s scientists can sign off on.

BHOmber

I have a feeling that we're never going to see another 2015-2016/early-2021 type run on these even with uplisting. I've been slowly consolidating my Cresco/Trulieve positions into GTI over the last couple years of pumps because I think they'll be the first CPG play, but idk how we're going to see those 10-15x off the lows like we did with APHA in 2021. It would take a full blue sweep with someone even moderately pro-industry for the stars to align. The 2021 thing was different because we had the presidential election followed by an uncertain runoff win in GA. It was perfect timing. This year's midterms could make a pop, but my prediction is that it will be similar to when the orange pedo said he was going to do something and then the entire admin was disrupted by another weekly scandal. 2x-5x-10x etc will depend solely on a candidate committed to opening up the US industry through pressuring the DEA and Congress for SAFE/Schedule II-V (or de-scheduling). Either way around it, I'll just hold this POS sector until the bombs drop or we somehow get past this fuckass timeline lol

boravuth

The Antelope @__OuttaControl_ Not spiking the football (and obv neither is the market) but two items dropped today that, read together, are worth noting for anyone tracking cannabis rescheduling. First: The Medicare CBD pilot launching April 1 will allow full-spectrum products, meaning trace THC is included. The government could have narrowed this to CBD isolate. They didn't. That's a quiet but meaningful acknowledgment of the entourage effect - that the combination of cannabinoids produces better clinical outcomes than CBD alone. You don't design a Medicare pilot around full-spectrum products without believing the THC interaction matters therapeutically. And before anyone says 'the hemp industry just lobbied for this' - Charlotte's Web would have taken isolate coverage and celebrated. The full-spectrum spec is a clinical design choice, not a lobbying win. Second: Rep. Reschenthaler (R-PA) introduced H.R.7987 today, creating a safe harbor for national securities exchanges to list cannabis companies and prohibiting federal adverse action against businesses that serve cannabis operators. Here's the dot-connect: Schedule I is defined as 'no currently accepted medical use.' The federal government is now covering full-spectrum cannabinoid products (including THC) for seniors through a physician-recommended Medicare pilot. You cannot hold both of those positions simultaneously forever. HHS already formally concluded in 2023 that cannabis has accepted medical use. The EO directed the AG to expedite rescheduling. The pilot is now building the real-world evidence record that makes DEA resistance increasingly indefensible. The rescheduling isn't done. 280E relief isn't here yet. But consider what today actually represents: on the same day a federal health agency quietly acknowledged that THC has therapeutic value by designing a Medicare pilot around it, a Republican congressman introduced legislation to let cannabis companies list on national exchanges. One is the scientific predicate. The other is the capital markets infrastructure. You don't build the second without the first eventually following. Cautious optimism is the right posture. But the architecture is taking shape 7:32 AM · Mar 19, 2026 · 15.2K Views

boravuth

The Antelope @__OuttaControl_ Not spiking the football (and obv neither is the market) but two items dropped today that, read together, are worth noting for anyone tracking cannabis rescheduling. First: The Medicare CBD pilot launching April 1 will allow full-spectrum products, meaning trace THC is included. The government could have narrowed this to CBD isolate. They didn't. That's a quiet but meaningful acknowledgment of the entourage effect - that the combination of cannabinoids produces better clinical outcomes than CBD alone. You don't design a Medicare pilot around full-spectrum products without believing the THC interaction matters therapeutically. And before anyone says 'the hemp industry just lobbied for this' - Charlotte's Web would have taken isolate coverage and celebrated. The full-spectrum spec is a clinical design choice, not a lobbying win. Second: Rep. Reschenthaler (R-PA) introduced H.R.7987 today, creating a safe harbor for national securities exchanges to list cannabis companies and prohibiting federal adverse action against businesses that serve cannabis operators. Here's the dot-connect: Schedule I is defined as 'no currently accepted medical use.' The federal government is now covering full-spectrum cannabinoid products (including THC) for seniors through a physician-recommended Medicare pilot. You cannot hold both of those positions simultaneously forever. HHS already formally concluded in 2023 that cannabis has accepted medical use. The EO directed the AG to expedite rescheduling. The pilot is now building the real-world evidence record that makes DEA resistance increasingly indefensible. The rescheduling isn't done. 280E relief isn't here yet. But consider what today actually represents: on the same day a federal health agency quietly acknowledged that THC has therapeutic value by designing a Medicare pilot around it, a Republican congressman introduced legislation to let cannabis companies list on national exchanges. One is the scientific predicate. The other is the capital markets infrastructure. You don't build the second without the first eventually following. Cautious optimism is the right posture. But the architecture is taking shape 7:32 AM · Mar 19, 2026 · 15.2K Views

Tiaan

I think that's a fair perspective, but I'd imagine they'd love a win right now as well as a distraction from the current headlines, and DOJ/DEA aren't really involved in the war

C_B_Doyle

Good question. Federal legalization risk is real but timing matters. Schedule III rescheduling (2–4 years) keeps cannabis in state hands. DEA doesn't create bulk federal licenses overnight. State licenses stay the moat through the 280E removal window. Full federal legalization with DEA consolidation is a different endstate and takes longer. By then MRMD either converts to federal holder (likely given track record), sells to larger operator, or operates as legacy state player in hybrid system. Canadian hedge makes sense if you think DEA moves fast and crushes regional players. But federal legalization after Schedule III lets MRMD capitalize on 280E tailwind first, then deal with federal licensing from position of strength—profitable, debt-light, established brands. Near term catalyst (280E) works regardless. Time to see how federal licensing plays out.

SwordfishOk504

> Under Biden, rescheduling was permitted to move forward, but without strong executive pressure, agencies like the DEA defaulted to caution, delays, and procedural drift. Under Trump, the posture appears fundamentally different. lol. We're well into year two of his presidency. What "posture shift"? The dEA is still slow walking it, four months after the meaningless Executive Order.

areyouhighson

It’s been a couple months and it’s still at the same standstill with the DEA. Two more weeks?

UsedState7381

The executive order was issued in December 18th and tomorrow it will have completed three months old already, so I don't know where you're taking 45 days from. Unless you're not counting the days the DOJ/DEA wasn't working(and far as I'm aware, the government shutdowns didn't stopped them).

AverageNo130

Well DEA has had this for almost 3 years.

KAI5ER

TLDR Under Biden, DEA had time to slow walk. Under Trump, they may not.

KAI5ER

The key dynamic here isn’t that the science or evidence around cannabis suddenly changed, but that the level of political urgency did. Under Biden, rescheduling was permitted to move forward, but without strong executive pressure, agencies like the DEA defaulted to caution, delays, and procedural drift. Under Trump, the posture appears fundamentally different. With clear presidential support, driven in part by close personal influence, the process shifts from passive review to active execution. That doesn’t guarantee a fast or smooth path, since the DEA and DOJ still need to build a legally defensible case, but it does change the trajectory. In practical terms, what was once a slow, uncertain bureaucratic process now carries the potential for acceleration, making rescheduling less about whether it happens and more about how quickly and cleanly it can be implemented.

AverageNo130

Republican Gov. Larry Rhoden signed a bill into law last week that sets the state up to instantly legalize crystalline polymorph psilocybin if the U.S. Food and Drug Administration approves its use and the U.S. Drug Enforcement Administration reschedules it from a drug of abuse to a drug with medical value. MM DEA ? Could be awhile.

Gambelero

Take an upvote guys. Just the kind of info that helps everyone on this board. To me, putting together regs for what is and what isn’t allowed in legal Cannabiol (CBD), setting up a pilot test system, and clarifying regs for Medicare coverage is way more difficult than finding enough medical benefits for marijuana to write a report that justifies rescheduling. Dr Oz or whoever is doing the heavy lifting for this seem to have gotten way more done than the DEA/FDA on S3. Even though the process for the pilot program is completely unrelated to the process for rescheduling and the program, itself, does little for our stocks’ valuation theses, it might chafe Bondi and Trump into pressuring the DEA into getting their work done.

C_B_Doyle

Good question. Federal legalization risk is real but timing matters. Schedule III rescheduling (2–4 years) keeps cannabis in state hands. DEA doesn't create bulk federal licenses overnight. State licenses stay the moat through the 280E removal window. Full federal legalization with DEA consolidation is a different endstate and takes longer. By then MRMD either converts to federal holder (likely given track record), sells to larger operator, or operates as legacy state player in hybrid system. Canadian hedge makes sense if you think DEA moves fast and crushes regional players. But federal legalization after Schedule III lets MRMD capitalize on 280E tailwind first, then deal with federal licensing from position of strength profitable, debt-light, established brands. Near term catalyst (280E) works regardless. Time to see how federal licensing plays out.

joan_goodman

War on DEA

UsedState7381

Enforcement policy and rules for the CBD program have been published by the FDA and submitted for OIRA review, means that the CBD program should be going on as scheduled in April. https://www.reginfo.gov/public/do/eoDetails?rrid=1312062 In the meantime, MSOS hasn't even traded 2M shares today, even though this + VA rec program are substantial news. It's starting to look like the CBD program will start without the DEA/DOJ issuing a final rule, just our fucking luck.

Gambelero

When the DEA and FDA scientists reach a consensus on the state of the science.

GeoLogic23

I still think a key event could be the DEA Supply Chain conference, which has usually happened in April. As far as i can tell no date has even been announced yet though. But keep an eye out for whenever that happens.

KAI5ER

We are once again at the mercy of the DEA/DOJ.

Twist_of_Fate_44

Interesting and NOT related other than procedural. There was a DEA update on the FedReg today, a Temp amendment, a new Temp ruling order to put Bromazolam on S1 It started with a proposed amendment on Dec 15/25 [https://www.federalregister.gov/documents/2025/12/15/2025-22763/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i](https://www.federalregister.gov/documents/2025/12/15/2025-22763/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i) Now three months to the day, we have a temporary amendment on March 16/26 [https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i](https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i) I guess this is what I found interesting, the timelines of action with the process [https://www.federalregister.gov/d/2026-05064/p-46](https://www.federalregister.gov/d/2026-05064/p-46) *As required by* [*21 U.S.C. 811(h)(4)*](https://www.govinfo.gov/link/uscode/21/811)*, the then-Acting Administrator transmitted to the Acting Assistant Secretary, via letters dated June 14, 2024, and June 11, 2025, notice of DEA's intent to place bromazolam in schedule I on a temporary basis. By letters dated June 28, 2024, and July 10, 2025, the Acting Assistant Secretary had no objection to the temporary placement of bromazolam in schedule I. DEA subsequently published this NOI in the* ***Federal Register*** *on December 15, 2025.**^(\[)*[*^(17)*](#footnote-17-p12507)*^(\])* Just another interesting tidbit, it's actually all worthy of a Sunday morning read: *The temporary placement of bromazolam in schedule I of the CSA will take effect on the date the order is published in the* ***Federal Register*** *and will remain in effect for two years, with a possible extension of one year, pending completion of the regular (permanent) scheduling process.**^(\[)*[*^(18)*](#footnote-18-p12507)*^(\])* *The CSA sets forth specific criteria for scheduling drugs or other substances. Permanent scheduling actions in accordance with* [*21 U.S.C. 811(a)*](https://www.govinfo.gov/link/uscode/21/811) *are subject to formal rulemaking procedures “on the record after opportunity for a hearing” conducted pursuant to the provisions of* [*5 U.S.C. 556*](https://www.govinfo.gov/link/uscode/5/556) *and* [*557*](https://www.govinfo.gov/link/uscode/5/557)*.**^(\[)*[*^(19)*](#footnote-19-p12507)*^(\])* *The permanent scheduling process of formal rulemaking affords interested parties appropriate process and the government any additional relevant information needed to make a determination. Final decisions that conclude the permanent scheduling process of formal rulemaking are subject to judicial review.**^(\[)*[*^(20)*](#footnote-20-p12507)*^(\])* *Temporary scheduling orders are not subject to judicial review.**^(\[)*[*^(21)*](#footnote-21-p12507)*^(\])* Document was signed on Mar 10/26, posted today March 14/26 and effective Monday the 16th [https://www.federalregister.gov/d/2026-05064/p-84](https://www.federalregister.gov/d/2026-05064/p-84) *This document of the Drug Enforcement Administration was signed on March 10, 2026, by Administrator Terrance C. Cole. That document with the original signature and date is maintained by DEA. For administrative purposes only, and in compliance with requirements of the Office of the Federal Register, the undersigned DEA Federal Register Liaison Officer has been authorized to sign and submit the document in electronic format for publication, as an official document of DEA. This administrative process in no way alters the legal effect of this document upon publication in the* ***Federal Register*** *.* If this was our sector, that's a whole lot of time to leak the news before hitting the FedReg!!! #

KAI5ER

Good margins and cash flow, but falling revenue reminds us the entire MSO sector is just grinding sideways until the DEA does something.

Astr0b0ie

Nah, it's pretty straightforward chemistry. The problem is that it requires anthranilic acid or N-acetylanthranilic acid (depending on the method of synthesis), both of which are list 1 precursor chemicals that are tracked and watched closely by the DEA. It also requires ortho-toluidine which is under DEA "special surveillance" and is a class 1 carcinogen. So between the difficulty of obtaining the required precursor chemicals, the attention that reintroducing a famous old drug would bring from law enforcement, and an unknown and unpredictable demand in North America and Europe, it just isn't worth the risk.

skyplt29

Watched Joe Rogan's recent podcast. I have mixed feelings about it. This guy supported Trump in 2024 and is now expressing "surprise and disappointment" that Trump pretty much lied about everything. Not sure why Rogan is now just seeing that. You have to question why he did not see this the first time around with Trump. So we continue to suffer in this sector while this war plays out and oil becomes unhinged. I am not sure how much more tone deaf Trump can be; he actually has the audacity this morning to suggest high oil prices are good for the country. It's fucking impossible to keep up with all the bullshit coming out of this government...or the previous government as well for that matter when it comes S3. Simple fact is DEA and FDA are either incompetent, or slow walking this on purpose regardless of whether the Democrats or Republicans are in charge. Just painful. If ever there was a time for Bondi to announce S3, it would be now. But this sector is pretty much past the point of any meaningful returns. That VFF is down 10 percent today is another testament to how screwed up this sector is. VFF is one of the most solid LPs out there. Nothing is making sense to me.

skyplt29

Yep...I am getting close to throwing in the towel on this sector. Holding on as I do believe Bondi is under pressure from Trump to move on S3. But as most of us here realize, this has been in the DEA's hands for years, and they have to give some consideration to all of those sniffer dogs that might be put out of work. Any of us who have been here for more than a year or two have pretty much seen every WTF moment imagineable.

Gambelero

Or Obama’s administration. That rescheduling attempt lasted six years and the DEA/FDA’s state if the science report rejected reclassification.

Cool_Ad_5101

So neither trump (so far) or Biden have successfully made the DEA hurry up. 

GreenGameboyColor

I hate people who take drugs. Specifically the police, DEA, and narcs

ShartSqueeze

We live in negative times. There's a high probability of negative war news tanking the market on open. We also know the DEA isn't gonna publish things on the weekend.

OorvanVanGogh

DEA doing what it does best - sabotage whatever change endagers its continued existence and funding.

AverageNo130

[](https://x.com/AMartinelliWA) [](https://x.com/AMartinelliWA)[15h](https://x.com/AMartinelliWA/status/2029723046391792111) A senior advisor to President Trump tells us the president is “very disappointed with Bondi’s inaction on cannabis rescheduling.” According to the advisor, Bondi says the delay is due to the DEA’s need to ensure everything is done in a legally valid manner, while continuing to imply a final order could be published within days, something she first said more than a month ago. The advisor says Trump wants the order posted before the forthcoming CBD Medicare program launches and is telling Bondi to do what it takes to get it done. The advisor also says it’s possible Bondi could be removed following Noem, citing rescheduling and other issues.

skyplt29

I want S3 as much as any other investor in this sector, but holy shit on a candlestick am I ever tired of rumors and innuendo. The DEA has been slow walking this for years now, closing in on a decade. That's where the focus should be, having DEA provide an update on their "due process". This sector has endured bullshit whispers and innuendo orchestrated to enrich few insiders and influencers. Legalize and regulate both cannabis and hemp.

AverageNo130

[AMartinelliWA](https://stocktwits.com/AMartinelliWA) \-A senior advisor to President Trump tells us the president is “very disappointed with Bondi’s inaction on cannabis rescheduling.” According to the advisor, Bondi says the delay is due to the DEA’s need to ensure everything is done in a legally valid manner, while continuing to imply a final order could be published within days, something she first said more than a month ago. The advisor says Trump wants the order posted before the forthcoming CBD Medicare program launches and is telling Bondi to do what it takes to get it done. The advisor also says it’s possible Bondi could be removed following Noem, citing rescheduling and other issues. 6:57 PM · Mar 5, 2026

Ok-Replacement9595

The AGs office has authority to sign the final order. She does not need DEA to do anything.

Ok_Recording_4440

Obviously Biden‘s DEA head had no interest in getting it pushed through quickly now that it’s turned over to Dea which I think was mistake there’s  no telling what kind of Fuckery could happen. If you’ve been following this, does anyone really think they’ll do all the eyes and cross all the tees or well? They half ass do it and leave holes in the process intentionally

GeoLogic23

To be fair, the Biden EO was to start the process, which then had to go through the whole HHS review before actually getting to the DEA. There was actual work that was done that we can see, and that's the whole reason we're even talking about Schedule 3. The DEA sat with it for a couple years now after that was finished. Trump's EO was literally just like "sign the thing". There isn't even any action that "should" be needed besides finalizing it, if the DEA had cared to do anything at all over the last 2 years.

bananastock

Pretty incredible how long this has taken. Two executive orders from presidents on both sides and yet the DEA has managed to continue to choke the process. No one really cares.

GeoLogic23

Everything is right around the corner for people whose paycheck depends on keeping you constantly engaged with them. He loses money if he tells you nothing is happening for a month. The DEA has had this for literally years. But now if Bondi does get fired (decent gamble to take) he can just say oh rescheduling is delayed because of that. I am still hoping it comes soon, because they need to straighten out what's going on with hemp in time for people to plant. And I'm still waiting for that DEA Supply Chain conference to get scheduled in April. If that passes before we get S3 I will be much more pessimistic about when it's going to occur.

ReformedRegent

"A senior advisor to President Trump tells us the president is “very disappointed with Bondi’s inaction on cannabis rescheduling.” According to the advisor, Bondi says the delay is due to the DEA’s need to ensure everything is done in a legally valid manner, while continuing to imply a final order could be published within days, something she first said more than a month ago. The advisor says Trump wants the order posted before the forthcoming CBD Medicare program launches and is telling Bondi to do what it takes to get it done. The advisor also says it’s possible Bondi could be removed following Noem, citing rescheduling and other issues." [https://x.com/amartinelliwa/status/2029723046391792111?s=46](https://x.com/amartinelliwa/status/2029723046391792111?s=46)

jmu_alumni

Yea some good and bad in that post if all true. She didn’t get fired right after her hearings like Noem did, so maybe a sign the firing of Bondi is not as preventant. I think the DEA is playing games with her and she somewhat has to take her staff for their word on the ‘issues’ they are facing getting this done. This tactic seemed to work on the previous administration as well and stonewall any progress the president/DOJ was trying to push for.

GeoLogic23

I also think/hope it'll be soon. They need to define THC cannabinoids and containers and stuff, which they missed the deadline for. But that is critical for defining hemp regulations. I've been saying for a while they really need to do everything at once. They can't have one announcement about hemp THC being legal and then another announcement saying marijuana THC is Schedule 3. Nobody knows the difference now, let alone after rescheduling. The big alcohol people don't want consumers to be confused whether or not their beverage products are legal. There is also the DEA Supply Chain conference. That is supposed to be in April and they always discuss cannabis stuff. Like a couple years ago, i think right around that time is the ideal time for an announcement. The public knowing what's going on is very important. However all the DEA supply chain stakeholders are the ones who the DEA really cares about informing. They care more about a competent rollout of THC that makes the DEA's life easier, as opposed to letting us retail investors turn a profit. They still have yet to say when they conference is happening though. They have typically done it by now.

Temporary-Alarm-744

I’m an DEA, and man I can firm

Wan4trulove

I mean .. not to give hopium , but if the admin can arm twist DEA/DOJ to issue final ruling by mid march . OMB will be piece of cake ...

KAI5ER

Sure. but the past has proven time and time again that these institutions take the maximum allotted length. We may have Swapped heads of DEA / DOJ but most of its employees are the same.

Wan4trulove

It seems that there is a misconception going around, if DOJ/DEA indeed planning to issue final ruling , it will need to go through OMB(OIRA) review first as cannabis rescheduling is a major rule and once OMB approval is done then it will hit federal register. It seems many people are refreshing federal register instead of OIRA website...

hambone_83

There are other companies exporting S3 substances as long as they have a DEA export permit and the receiving country allows the substance for medical/scientific purposes. Ketamine and testosterone can be exported from the US and those are both S3 substances. If reclassification occurs there needs to be guidance around how the new substance are governed at a federal level. Add to that if they are thinking of putting full spectrum CBD into the Medicare program they are going to have to ease the restrictions to allow this to happen. Hence my original point that there is a possibility that exporting to another country might happen before interstate. Might be only CBD, or low-THC or something else, but there is a real possibility of it happening.

Twist_of_Fate_44

Here's what to do Everyday between 8:45-9:15AM ET check the Federal Register Go to: Federal Registry Search Search: "marijuana rescheduling" Agency: DEA Search: Newest If it's not posted by 9:15AM, then no need to re-check till the next day You can also look on the DEA page under Drug Scheduling to see if it's moved from SC1 to 2-5 All the other noise is just the MMs and the various online personas dropping falsities

Gambelero

Good catch. Makes you wonder where they are in the process. Are they redoing the DEA/FDA state of the science report? To us, that seems like a big waste of time. If the moved forward with what the Biden administration already did, though, that might lead to the credit for moving to S3 will be split and that’s something Trump would totally not allow. The argument could also be made that the original 250 page report was thrown together without getting the scientists to approve it (the proposed rule didn’t come from the DEA/FDA, but was instead promulgated by political appointees in the Justice Department). And that was why it wasn’t doing well in the alj hearing.

Ok_Recording_4440

Sam seems to know as they I assume have close contact with fellow Prohibitionist DEA agents. Kevin already seems to be acknowledging medical use on twitter from what I saw. The AV video thing really was a black eye. I do like his input but to be clear he’s obv not gonna make money staying quiet about the space which means continuing spec and banter

C_B_Doyle

Cannabis is moving toward pharmaceutical cannabis, meaning formal research, pharmacy distribution, hospital use, and insurance coverage, which lowers cost and raises access by shifting it from weed shop to medicine. If that shift happens, not all companies win; the early winners are the ones already built like medical operators, and MariMed fits that profile with established patient products, multi state operations, low debt, and a focus on medical demand instead of hype. Odds favor rescheduling because the DEA, FDA, and lawmakers are already aligned in that direction, and if it happens, pharmaceutical cannabis companies like MariMed benefit first because they are already operating as if the rules have changed.

Ok_Recording_4440

No I can’t either. Seems like the all the admin chatter acknowledges schedule 3. Now if DEA does final rule will we get a new admin judge and have all that drawn out rule hearing stuff idk. Would certainly cause a pullback vs straight to final rule which will be challenged. Challenged or not it’s the final stretch at that point. 

IllCamel5907

If it were up to DEA prohibitionist Terry Cole the entire rescheduling process would be put in reverse and marijuana would remain schedule 1.

TroubledAcorn

We no longer need the DEA. DOJ can make the ruling on their own

C_B_Doyle

Cannabis may soon be moved to a safer legal category by the government. If that happens, doctors can study it more, pharmacies can sell it, hospitals can use it, and insurance can help pay for it. That means medical cannabis becomes cheaper, safer, and easier for patients to get. This is the pathway from weed shop to real medicine. If this change happens, not every cannabis company wins. The ones that already act like medical companies have better odds. MariMed makes products patients already use like gummies, RSO, flower, and concentrates. They operate in many states, keep debt low, and focus on medical users instead of hype. What are the odds. Rescheduling is more likely than not because the DEA, FDA, and politicians are already moving in that direction. If it happens, companies built for medicine benefit first. MariMed is already there, waiting. #MRMD

KAI5ER

The DEA is the bottleneck,

LaserAid69

Oof this is so annoying. I was up on my MSOS position yesterday and today down. Glad it’s only shares but still… when the fuck is the DEA gonna make their announcement?

aj1805

I’m wary of the DEA completing the rule making in a timely manner. It would be great to see the hemp definitions updated before the ban officially take place.

C_B_Doyle

Federal cannabis policy: the December 18, 2025 executive order directs the DOJ/DEA to finish rescheduling marijuana from Schedule I to Schedule III to ease research and medical access, but it hasn’t taken legal effect yet because the DEA still must complete formal rulemaking and publish a final rule. For CBD in primary healthcare, the order also pushes federal agencies to work with Congress to update hemp/CBD definitions so patients can access appropriate full-spectrum CBD products, but no broad healthcare coverage mandates are finalized yet.

C_B_Doyle

With the anticipated rescheduling of cannabis by the DEA and subsequent FDA research into its medical value, I believe we are on the brink of a significant shift. This change could pave the way for cannabis to be distributed through pharmacies like Walgreens and integrated into hospital treatment plans. Insurance companies, through co-pay systems, could further reduce patient costs, making medical cannabis as accessible as traditional medications. Among the companies poised to benefit from this shift is MariMed Inc. (MRMD). MariMed stands out due to its: Diverse Product Portfolio: Gummies, RSO, ice cream, flower, live resin, and other medical-grade products. Efficient Licensing Strategy: Operating across multiple states with minimal debt, positioning it for scalable growth. Focus on Medical Applications: Their emphasis on innovation and patient-focused solutions aligns with the projected medical cannabis market. Given the convergence of regulatory changes and market potential, MariMed is uniquely positioned to integrate efficiently into the pharmaceutical and medical sectors. I’d love to hear your thoughts on this opportunity and how it aligns with your investment strategy. Please feel free to contact me at your convenience.

KAI5ER

I have two different thoughts on the DOJ right now. First is that the DOJ is probably in overdrive trying to deal with an abnormal presidency. So something like S3, (even if its on Bondis desk) might be delayed because of it. Second is that the DEA is probably just as opposed to S3 as it was under the Biden admin. If the DEA requires involvement, expect everything to be 30 - 90 days (whatever the max is)

Gambelero

General reply to the thread and the replies, I don’t think they’ll wait even a minute for S3 or anything else. They’ll move S3 forward as soon as the DEA state of the science task force finishes its report. And they’ll move forward with the pilot CBD program as soon as they finish working out the details.

GeoLogic23

I think the much more relevant date in April will be whenever they schedule the 2026 DEA Supply Chain Conference. I feel like they have typically had a date by now, but they haven't announced anything yet.

UsedState7381

It's important, but the "action" they say they took hasn't really materialized any meaningful change because the problem is at the DOJ and DEA.

KAI5ER

I look at it this way. He mentioned taking action to change to S3, but also a need for more research (S3 required again). I think it looks very bad for legalization under a trump admin, But Im still positive the Whitehouse wants S3. DEA/Sentate is another story.

Ok_Recording_4440

Hasn’t she turned it over to the DEA to release final rule. Which you could argue as in a good thing either, but at least some of the reports I saw from MH and questionable pedophile Matt Gates was that the DEA was going to release the final rule. If she can defend all this Epstein stuff for the president she’ll do the rescheduling. It’s just annoying. We should’ve already had all this paperwork and stuff ready to rock. I don’t understand the waiting part.

the_mammynun

Definitely. Personally I lost hope this week as I don't think Bondi or the DEA care to expedite this. It could be sitting on her desk until the next federal election. As far as I'm concerned this will only happen if Trump himself doubles down. Glad I only hold HITI but no S3 means flat/downtrend for all canna stocks.

C_B_Doyle

#MRMD 🌳 With the anticipated rescheduling of cannabis by the DEA and subsequent FDA research into its medical value, I believe we are on the brink of a significant shift. This change could pave the way for cannabis to be distributed through pharmacies like Walgreens and integrated into hospital treatment plans. Insurance companies, through co-pay systems, could further reduce patient costs, making medical cannabis as accessible as traditional medications. Among the companies poised to benefit from this shift is MariMed Inc. (MRMD). MariMed stands out due to its: Diverse Product Portfolio: Gummies, RSO, ice cream, flower, live resin, and other medical-grade products. Efficient Licensing Strategy: Operating across multiple states with minimal debt, positioning it for scalable growth. Focus on Medical Applications: Their emphasis on innovation and patient-focused solutions aligns with the projected medical cannabis market. Given the convergence of regulatory changes and market potential, MariMed is uniquely positioned to integrate efficiently into the pharmaceutical and medical sectors. I’d love to hear your thoughts on this opportunity and how it aligns with your investment strategy. Please feel free to contact me at your convenience.

King_Chron

I actually did read the filings. You're right that the leverage looks "comical" compared to a fortress balance sheet like GTI’s, but calling it scary right now ignores the fact that they literally just **de-risked the next three years.** The whole "debt wall" argument died this morning because they just **secured commitments for $500M in new notes** at 11.5%, which **kicks that 2026 maturity bucket all the way to 2029.** Institutional lenders aren't in the business of charity; they wouldn't oversubscribe a half-billion-dollar deal if the company was a guaranteed zero. And while everyone is waiting for S3 like it’s the messiah, Curaleaf is **already out-earning their interest** under current laws. They pulled in over **$104M in operating cash flow** through the first nine months of 2025 against about $75M in interest. Even with the new $500M note adding roughly **$57M in annual interest**, their current trajectory of **$330M+ in quarterly revenue** and stabilizing margins **means they can service the debt out of existing operations**. Plus, they’re the only ones aggressive enough to **stop paying the 280E tax load** entirely while they fight it in court, which gave them a **$110M cash cushion** to bridge the gap to this refi. You’re also forgetting that they have a massive head start in Europe while everyone else is fighting for scraps in oversupplied US states. Their **International revenue jumped 56% to $25.5M last quarter alone**, and they’re sitting on **50% adjusted gross margins** in that segment. While the US bears wait for a political miracle, Curaleaf is already scaling in Germany and the UK. That **Euro-revenue is a secondary engine** that isn’t 100% dependent on the Executive Order or the DEA’s timing. Is it a high-beta, high-leverage play? Absolutely. But the "imminent collapse" thesis just got pushed back three years by a **successful $500M raise.** **Yes they are dependent of Schedule 3 coming**. and have pushed their can 3 years back to time it. now do you want to take the other side of their bet is the question? **Schedule 3 is on the way**.....

UsedState7381

I'm fully expecting her to give us a non-awnser because that has been her default in regards to this matter since her Senate confirmation hearing. However, I remain hopeful that we will S3 finalized before midterms, if the DEA and DOJ are quick and competent, we can even get S3 final rule published before the CBD program goes live.

UsedState7381

It's funny, because about two to three weeks ago he was saying that he wasn't thinking of days or weeks about the timing of S3 final rule. He believes that the final rule will drop before the CBD program goes live in April. I can see the reasoning why, but I remain skeptical of the DOJ's and DEA's competence to pull it off before that deadline. Also, the CBD in that program is not derived of THC at all, so S3 barely has any relation at all to it.

skyplt29

Perhaps a review of DEA's scheduling definitions will clarify what rescheduling marijuana from 1 to 3 means: **Schedule I** Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Some examples of Schedule I drugs are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote. **Schedule II** Schedule II drugs, substances, or chemicals are defined as drugs with a high potential for abuse, with use potentially leading to severe psychological or physical dependence. These drugs are also considered dangerous. Some examples of Schedule II drugs are: combination products with less than 15 milligrams of hydrocodone per dosage unit (Vicodin), cocaine, methamphetamine, methadone, hydromorphone (Dilaudid), meperidine (Demerol), oxycodone (OxyContin), fentanyl, Dexedrine, Adderall, and Ritalin **Schedule III** Schedule III drugs, substances, or chemicals are defined as drugs with a moderate to low potential for physical and psychological dependence. Schedule III drugs abuse potential is less than Schedule I and Schedule II drugs but more than Schedule IV. Some examples of Schedule III drugs are: products containing less than 90 milligrams of codeine per dosage unit (Tylenol with codeine), ketamine, anabolic steroids, testosterone **Schedule IV** Schedule IV drugs, substances, or chemicals are defined as drugs with a low potential for abuse and low risk of dependence. Some examples of Schedule IV drugs are: Xanax, Soma, Darvon, Darvocet, Valium, Ativan, Talwin, Ambien, Tramadol **Schedule V** Schedule V drugs, substances, or chemicals are defined as drugs with lower potential for abuse than Schedule IV and consist of preparations containing limited quantities of certain narcotics. Schedule V drugs are generally used for antidiarrheal, antitussive, and analgesic purposes. Some examples of Schedule V drugs are: cough preparations with less than 200 milligrams of codeine or per 100 milliliters (Robitussin AC), Lomotil, Motofen, Lyrica, Parepectolin

romanticynicist

It’s also more pure than it used to be. Even if you thought the war on drugs was a good idea, it’s pretty damning that most drugs have gotten both cheaper and more pure in the decades it’s been going on. This is according to the DEA’s own statistics, as well as plenty of others.

Mother___Night

DEA is just following the regular rule change procedure. It's going to happen eventually.

emperor_dinglenads

I can't imagine bagholding weed stocks anymore. Donald Trump signed an EO to reschedule weed and the DEA told him to kick rocks. ByRon tried to reschedule. Somehow D8 is now more illegal than it used to be. The only thing getting smoked is my tendies.

TCNNF_Moon-_

Funny the DEA has time to approve some company to buy cocaine legally for “Research” 🧐 But can’t find the time to reschedule cannabis.

UsedState7381

Executive Order is signed already, also RFK was literally there at the office thanking Trump for rescheduling cannabis. The HHS ranks leagues above the ONDCP in these matters, and in the end it's still the DOJ and DEA call. That's not happening. Also, >That’s why we reiterate our call that the director of ONDCP should be elevated to the Cabinet-level status the position once enjoyed: our drug crisis demands nothing less.  That's on the same weblink posted here. All of this is beyond her power.

UsedState7381

So....How long do you guys believe that Pam Bondi has left before kicks her out of the DOJ? I think she has a week left now. Now it makes a little more sense that Gaetz said it's the DEA that is drafting the final rule 😂 ...Oh God 

pink_ego_box

DEA guy looking for tips?

No_Love_Gained

Here is a list of pathways articulated, I am sure you've seen this already, but still sharing for awareness. https://www.jdsupra.com/legalnews/cannabis-in-2026-part-i-marijuana-1805293/#:~:text=On%20January%206%2C%202026%2C%20DEA,legislation%20enacted%20in%20late%202025)

Ok-Replacement9595

He retired after November. He saw the writing on the wall. AG had yo intervene in the process to get DEA out of the way after the proposed rule making period ended, also. Law enforcement is inherently reactionary and conservative. That is why they do what they do, including postponing, sidelining, and outright denial of judicial review as they did in the case of MDMA scheduling.

King_Chron

its hard to speculate on why they did these things.......frame looks less as a political play and more as a timing/optics issue: the DEA may have simply expected the process to get less attention with a new president-elect in office. The HHS recommendation came about a year before the election, and then the ALJ retired, which naturally paused the formal process without implying any improper motive. ([cannabisbusinesstimes.com](https://www.cannabisbusinesstimes.com/cannabis-rescheduling/news/15751360/dea-judge-overseeing-cannabis-rescheduling-hearing-set-to-retire?utm_source=chatgpt.com))

Ok-Replacement9595

I would argue they were never a block to the final outcome, but a delay by DEA until a presumably more advantageous presidency for them. I don't think it worked out that well, but the delay was clearly yo remove a policy win from Biden. I don't see the second statement anywhere in the second link, but whatever. It doesn't matter that much to me. We will all have to wait and see how it proceeds. I expect conservative groups to file a plethora of lawsuits after the final tule is published.

King_Chron

the ALJ paused the hearings in Jan 2025 pending an interlocutory appeal and then retired mid‑2025; no new ALJ has been publicly assigned, so the formal hearing phase remains stalled. ([cannabisbusinesstimes.com](https://www.cannabisbusinesstimes.com/cannabis-rescheduling/news/15751360/dea-judge-overseeing-cannabis-rescheduling-hearing-set-to-retire?utm_source=chatgpt.com)) That said, the December 18, 2025 Executive Order doesn’t nullify administrative process — it directs DOJ/HHS/DEA to finish the rulemaking “in the most expeditious manner permitted by law,” which means agencies can’t use the lack of an ALJ or other procedural pauses as an excuse to stall indefinitely. --------That phrasing does two things: (a) it makes completing the rulemaking an express White House priority, and (b) it reduces the cover agencies previously used to justify indefinite delays -------because further delay becomes an arguable failure to follow the President’s directive and can invite judicial/congressional enforcement. This gets into APA (Administrative Procedure Act)lawsuits ......([presidency.ucsb.edu](https://www.presidency.ucsb.edu/documents/white-house-fact-sheet-president-donald-j-trump-increasing-medical-marijuana-and?utm_source=chatgpt.com)) So yes, the administrative‑law mechanics still matter, but they’re now largely a timing issue rather than a blocker of the ultimate outcome. ([blankrome.com](https://www.blankrome.com/publications/hold-your-horses-cannabis-rescheduling-hearings-stayed-pending-appeal?utm_source=chatgpt.com))

Ok-Replacement9595

There were ongoing hearings in the administrative law process, which may or may not be necessary to the process. There is likely going to any judge replacing the DEA judge in charge of this case. There are other judges, but no word of the hearings proceeding. You seemed to be speaking authoritatively about that process, and the state of the case. I wondered if you had any knowledge of the administrative law review moving forward or not. You seem to be under the impression that it is just a moot point under the EO, which grants "authority" in some weird way to DEA specifically to complete the process. I don't know enough about administrative law to know, and can admit that, which is why I asked. I understand it is a review of the process in most cases. To find out if the correct process was adhered to under the policy and statutes pertaining to the process. It is a checkbox that usually had to get checked in changing policy internally or deciding cases that would open the agency to litigation. I was wondering if you had followed whether or not the administrative law review actually was going to continue. Some people beleive there is a stay in place from the previous judge. But honestly I haven't looked into it. I am at the point where if it happens it happens.

ZealotOfCannabis

>According to an advisor to President Trump, AG Bondi informed multiple people this week that the DEA will publish a final cannabis rescheduling order "in a matter of days". This means if the agency doesn't meet Trump's end-of-January directive, it likely won't be missed by much. [https://x.com/AMartinelliWA/status/2016996104022478925](https://x.com/AMartinelliWA/status/2016996104022478925) No one seems to believe it so we'll see what happens in the next few days/weeks

King_Chron

the executive order from Trump gives the DEA Administrator authority to move the rulemaking forward. So while the hearing is technically stalled, **the EO ensures Schedule III isn’t blocked — any delay now just affects timing, not the outcome**.

Ok-Replacement9595

What happens to those hearings without any administrative law judge at DEA? I am pretty certain that the GOP is against the process of agency employed administrative law judges since they sued several times against the process for other agencies.

King_Chron

I don’t dispute that the DEA previously used procedure to delay.....the record supports that....... That’s exactly why the EO matters. It explicitly directs DOJ, HHS, and DEA to complete Schedule III rulemaking expeditiously and in coordination, which removes their ability to hide behind internal process indefinitely. They can still follow the law, but they can’t slow-walk it anymore. At this point, delay affects timing, not outcome. Schedule III is a when, not an if.

KAI5ER

n a move that could significantly impact the [cannabis reform landscape](https://www.benzinga.com/topic/cannabis-reform?utm_campaign=partner_feed&utm_source=yahooFinance&utm_medium=partner_feed&utm_content=site&nid=40567326), the **Drug Enforcement Administration** (DEA) announced a delay on Monday in the rescheduling of marijuana, noting it would hold an administrative hearing for December 2, which pushes any decision on the matter until after the [2024 election](https://www.benzinga.com/topic/2024-election?utm_campaign=partner_feed&utm_source=yahooFinance&utm_medium=partner_feed&utm_content=site&nid=40567326). [https://finance.yahoo.com/news/dea-delays-cannabis-rescheduling-decision-022441964.html](https://finance.yahoo.com/news/dea-delays-cannabis-rescheduling-decision-022441964.html)

manualCAD

What does the DEA even do at the administrative, white collar level? Seems like they just do paperwork for Big Pharma to continue administering fentanyl and fentanyl derivatives. Do something else, guys.

King_Chron

Ah yes, DEA smash things fast, drag feet slow....... very great analysis. Meanwhile, real Schedule 3 rescheduling involves careful HHS review, decades of abuse potential studies, medical use evidence, and federal regulatory checks......not grunts or swings of a club. But sure, your one-sentence caveman wisdom totally explains bureaucracy!

King_Chron

Right, because clearly Milgram’s oral diplomacy is the real bottleneck in DEA Schedule 3 cannabis policy.........Meanwhile, the DEA and HHS are still doing the boring stuff...... analyzing pharmacology, abuse risk, and medical use....

King_Chron

The idea that agencies would ignore rescheduling is off-base. The process stalled under the last administration not because the DEA or HHS refused to act, but because of procedural hurdles and an administrative appeal. In early 2025, a hearing to evaluate reclassifying cannabis from Schedule I to Schedule III was paused due to an interlocutory appeal, and later the DEA’s chief Administrative Law Judge retired, leaving the case without a judge to preside. These delays are procedural, not a refusal to comply with the law. What’s different now is the executive order from Trump, which explicitly directs the DOJ, HHS, and DEA to complete the Schedule III rulemaking in the most expeditious manner in accordance with federal law. This restarts and accelerates the stalled process, and agencies cannot legally refuse to follow it. For U.S.-domiciled MSOs, the Schedule III catalyst remains very real.

King_Chron

Honestly, that sounds more like a conspiracy than reality. The HHS and DEA follow the law and the process set by the president and Congress. Schedule III rescheduling isn’t arbitrary — it goes through a formal statutory review. There’s no evidence that agencies refuse to comply; historically, these processes are slow but ultimately legal mandates are followed. For investors, the key takeaway is that if Schedule III is finalized, the structural upside for U.S.-domiciled MSOs is real. 280E taxes drop, cash flow jumps, and institutional investors can finally enter. Betting on regulatory non-compliance is much riskier than betting on the law actually being implemented.

jmu_alumni

“I have been told that the DEA is drafting this rule and moving it ASAP” I agree this means they are doing the heavy lifting (which could be argued was already done pre ALJ hearing by the dea), but I read this as they will aslo be the ones signing off on the final rule (since they are drafting it). But I do know your position is we are lightyears away from final rule and additional steps (like hiring AL judge is needed). Anyways, I hope we are both wrong and that DOJ will make the final rule over the next few weeks :)

King_Chron

You can’t really separate the two — federal medical use of CBD isn’t possible without a rescheduling step first. Any update alone, like FDA guidance or news, doesn’t change the fact that the DEA has to adjust the schedule. In practice, rescheduling and medical approval go hand in hand: one can’t happen without the other.